Preclinical Modeling of Combination Treatments: Fantasy or Requirement?-Reference-Cited by-同舟云学术

Preclinical Modeling of Combination Treatments: Fantasy or Requirement?

Published:2005-11 Issue:1 Volume:1059 Page:61-69
ISSN:0077-8923
Container-title:Annals of the New York Academy of Sciences
language:en
Short-container-title:

Author:

DECKER SHANNON,SAUSVILLE EDWARD A.

Publisher

Wiley

Subject

History and Philosophy of Science,General Biochemistry, Genetics and Molecular Biology,General Neuroscience

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1196/annals.1339.024/fullpdf

Reference19 articles.

1. Combination versus single agent chemotherapy: a review of the basis for selection of drug treatment of cancer;DeVita;Cancer,1975

2. In vitro preclinical models for a rational design of chemotherapy combinations in human tumors;Zoli;Crit. Rev. Oncol./Hematol.,2001

3. The hallmarks of cancer;Hanahan;Cell,2000

4. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis;Viloria-Petit;Cancer Res.,2001

5. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer;Hurwitz;N. Engl. J. Med.,2004

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Network-informed discovery of multidrug combinations for ERα+/HER2-/PI3Kα-mutant breast cancer;Cellular and Molecular Life Sciences;2023-03

2. Does Combination of DNR and Casticin show advantage in favor of apoptosis on AML leukemia stem-like cell lines? A preliminary study;Journal of Research in Pharmacy;2023

3. Network-informed discovery of multidrug combinations for ERα+/HER2-/PI3Kα-mutant breast cancer;2022-09-03

4. Radiation therapy and molecular‐targeted agents in preclinical testing for immunotherapy, brain tumors, and sarcomas: Opportunities and challenges;Pediatric Blood & Cancer;2020-08-22

5. Implementation of the Chou-Talalay method for studying the in vitro pharmacodynamic interactions of binary and ternary drug combinations on MDA-MB-231 triple negative breast cancer cells;Synergy;2019-06